193 related articles for article (PubMed ID: 36735782)
21. PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin.
Canals Hernaez D; Hughes MR; Dean P; Bergqvist P; Samudio I; Blixt O; Wiedemeyer K; Li Y; Bond C; Cruz E; Köbel M; Gilks B; Roskelley CD; McNagny KM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243933
[TBL] [Abstract][Full Text] [Related]
22. Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.
Binder ZA; Siu IM; Eberhart CG; Ap Rhys C; Bai RY; Staedtke V; Zhang H; Smoll NR; Piantadosi S; Piccirillo SG; Dimeco F; Weingart JD; Vescovi A; Olivi A; Riggins GJ; Gallia GL
PLoS One; 2013; 8(10):e75945. PubMed ID: 24146797
[TBL] [Abstract][Full Text] [Related]
23. Application of miR-193a/WT1/PODXL axis to estimate risk and prognosis of idiopathic membranous nephropathy.
Zhang W; Ren Y; Li J
Ren Fail; 2019 Nov; 41(1):704-717. PubMed ID: 31352863
[No Abstract] [Full Text] [Related]
24. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice.
Lee RH; Seo MJ; Pulin AA; Gregory CA; Ylostalo J; Prockop DJ
Blood; 2009 Jan; 113(4):816-26. PubMed ID: 18818395
[TBL] [Abstract][Full Text] [Related]
25. Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer.
Forse CL; Yilmaz YE; Pinnaduwage D; O'Malley FP; Mulligan AM; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2013 Feb; 137(3):709-19. PubMed ID: 23288345
[TBL] [Abstract][Full Text] [Related]
26. Podocalyxin in Normal Tissue and Epithelial Cancer.
Le Tran N; Wang Y; Nie G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201212
[TBL] [Abstract][Full Text] [Related]
27. Identification of LEA, a podocalyxin-like glycoprotein, as a predictor for the progression of colorectal cancer.
Yuan D; Chen H; Wang S; Liu F; Cheng Y; Fang J
Cancer Med; 2018 Oct; 7(10):5155-5166. PubMed ID: 30277651
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
Larsson A; Johansson ME; Wangefjord S; Gaber A; Nodin B; Kucharzewska P; Welinder C; Belting M; Eberhard J; Johnsson A; Uhlén M; Jirström K
Br J Cancer; 2011 Aug; 105(5):666-72. PubMed ID: 21829192
[TBL] [Abstract][Full Text] [Related]
29. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
[TBL] [Abstract][Full Text] [Related]
30. Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling.
Fröse J; Chen MB; Hebron KE; Reinhardt F; Hajal C; Zijlstra A; Kamm RD; Weinberg RA
Cell Rep; 2018 Jul; 24(4):962-972. PubMed ID: 30044991
[TBL] [Abstract][Full Text] [Related]
31. Radiation-Induced Overexpression of TGFβ and PODXL Contributes to Colorectal Cancer Cell Radioresistance through Enhanced Motility.
Lee H; Kong JS; Lee SS; Kim A
Cells; 2021 Aug; 10(8):. PubMed ID: 34440856
[TBL] [Abstract][Full Text] [Related]
32. Control of cell adhesion and migration by podocalyxin. Implication of Rac1 and Cdc42.
Fernández D; Horrillo A; Alquezar C; González-Manchón C; Parrilla R; Ayuso MS
Biochem Biophys Res Commun; 2013 Mar; 432(2):302-7. PubMed ID: 23396057
[TBL] [Abstract][Full Text] [Related]
33. Role of transcription factor Sp1 and CpG methylation on the regulation of the human podocalyxin gene promoter.
Butta N; Larrucea S; Alonso S; Rodriguez RB; Arias-Salgado EG; Ayuso MS; González-Manchón C; Parrilla R
BMC Mol Biol; 2006 May; 7():17. PubMed ID: 16684343
[TBL] [Abstract][Full Text] [Related]
34. First identification of
Lin FJ; Yao L; Hu XQ; Bian F; Ji G; Jiang GR; Gale DP; Ren HQ
Clin Sci (Lond); 2019 Jan; 133(1):9-21. PubMed ID: 30523047
[TBL] [Abstract][Full Text] [Related]
35. Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma.
Lin CW; Sun MS; Wu HC
Int J Oncol; 2014 Aug; 45(2):710-8. PubMed ID: 24821609
[TBL] [Abstract][Full Text] [Related]
36. Podocalyxin as a Prognostic Marker in Gastric Cancer.
Laitinen A; Böckelman C; Hagström J; Kokkola A; Fermér C; Nilsson O; Haglund C
PLoS One; 2015; 10(12):e0145079. PubMed ID: 26674770
[TBL] [Abstract][Full Text] [Related]
37. Additive clinical impact of epidermal growth factor receptor and podocalyxin-like protein expression in pancreatic and periampullary adenocarcinomas.
Heby M; Karnevi E; Elebro J; Nodin B; Eberhard J; Saukkonen K; Hagström J; Mustonen H; Seppänen H; Haglund C; Jirström K; Larsson AH
Sci Rep; 2020 Jun; 10(1):10373. PubMed ID: 32587323
[TBL] [Abstract][Full Text] [Related]
38. PODXL might be a new prognostic biomarker in various cancers: a meta-analysis and sequential verification with TCGA datasets.
He S; Du W; Li M; Yan M; Zheng F
BMC Cancer; 2020 Jul; 20(1):620. PubMed ID: 32615943
[TBL] [Abstract][Full Text] [Related]
39. Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.
Larsson A; Fridberg M; Gaber A; Nodin B; Levéen P; Jönsson G; Uhlén M; Birgisson H; Jirström K
BMC Cancer; 2012 Jul; 12():282. PubMed ID: 22769594
[TBL] [Abstract][Full Text] [Related]
40. Serum podocalyxin levels correlate with carotid intima media thickness, implicating its role as a novel biomarker for atherosclerosis.
Shoji M; Takemoto M; Kobayashi K; Shoji T; Mori S; Sagara JI; Kurosawa H; Hirayama Y; Sakamoto K; Ishikawa T; Koshizaka M; Maezawa Y; Yokote K
Sci Rep; 2018 Jan; 8(1):245. PubMed ID: 29321582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
